At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Observational (other)
- How long the study runs
- Study runs about 184 months (dates as stated)
- About the drug or intervention
- Observational — other: The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification.
- Patient visit burden
- Not specified by the sponsor
In plain English
This European study, run by the European Organisation for Research and Treatment of Cancer (EORTC), looks at how people with primary brain tumours are treated and what their outcomes are. Researchers will use tumour tissue samples and scans, along with newer ways of classifying brain tumours, to learn more about these cancers. It is an observational study, which means it looks at information rather than testing a new treatment. The exact start date, location and contact details are not stated — ask the trial team.
Who can take part
- Adults old enough to give their own consent.
- Have a newly diagnosed or recurring (returned) primary brain tumour that fits one of the study's groups of interest, such as glioma, ependymoma, embryonal tumour or other listed brain tumour types.
- Have stored tumour tissue from surgery available at the hospital. Tissue from the first surgery is preferred, but tissue from later surgery is allowed (except for group 16, where only tissue from the first surgery is allowed).
- Have MRI or CT scans available from when the brain tumour was first diagnosed. (MRI is magnetic resonance imaging, a detailed scan; CT is computed tomography, another type of scan.)
- Agree (give consent) to take part.
- For people who have died: their data, tissue or scans can be used if they agreed during their lifetime, if a relative gives consent, or if there is a legal declaration covering this situation. In all cases, the person must not have objected to research use during their lifetime, an ethics committee must be told, and any other national rules must be followed.
Who may not be able to
- Not stated — ask the trial team. The data only lists who can join, not specific reasons for exclusion.
What taking part involves
- • No treatment is given as part of this study. It is observational, meaning researchers study existing tissue samples, scans and health records.
- • Your stored tumour tissue and your MRI or CT scans from diagnosis will be reviewed by researchers.
- • Your medical information about your treatment and outcomes will be collected and studied.
Time commitment: Taking part involves sharing your stored tumour tissue, scans and medical records for research — the number of visits and how long the study lasts are not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 1,650
- Started
- 2023-03-21
- Last checked
- 2025-12
Plain English Summary
What is this study?
- • Testing a new treatment for glioma
- • Clinical study - 1,650 participants
- • Every new classification depends on its prognostic power and on the type of treatment given
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with glioma
Where?
- • Edinburgh - NHS Lothian - The Royal Infirmary Of Edinburgh
- • Newcastle upon Tyne - Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care
- • Nottingham - Nottingham University Hospitals NHS Trust - City Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Age ≥ legal age of consent
- ✓Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest
- ✓Available MRI/CT scans from primary brain tumour at initial diagnosis
- ✓Patient's consent
- ✓Deceased patient:
See the full criteria
Where Is This Study? (3 UK sites)
NHS Lothian - The Royal Infirmary Of Edinburgh
Edinburgh EH16 4SA, United Kingdom
Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care
Newcastle upon Tyne, United Kingdom
Nottingham University Hospitals NHS Trust - City Hospital
Nottingham, United Kingdom
How to Get in Touch
EORTC HQ
Sponsor contactCONTACT